Definitive Contract 75N91024C00009
Award Date 2/15/24
Potential Completion Date 4/14/25
Potential Value $355K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Plainsboro Township, NJ 08536, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
27
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Atux Iskay Group LLC, a for-profit limited liability company. The $400,000 firm-fixed price contract will support the development of senotherapeutic agents for cancer treatment. This is a total small business set-aside contract, with work to be performed primarily in Plainsboro Township, New Jersey. The contract stems from a...
- This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
- This is a Small Business Innovation Research (SBIR) Phase I Concept Award from the National Cancer Institute (NCI), a civilian agency, to Tippingpoint Biosciences, Inc., a woman-owned small business. The $355,000 firm-fixed-price contract is for research and development activities to demonstrate technical feasibility and proof-of-concept for the development of innovative and potentially transformative therapeutic, device, diagnostic, or digital health technologies targeting Pediatric Cancers...
- This is a $300,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Coordination Pharmaceuticals Inc., a small business. The contract is for the detection, diagnosis, treatment, prevention, and research of pediatric cancers and/or rare cancers. It was awarded under a Small Business Innovation Research (SBIR) Concept Award Program, which is a "Phase 0" pilot program intended to encourage small businesses to develop innovative and...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $355,000 Firm Fixed Price contract was awarded to Insilicom LLC, a minority-owned and woman-owned small business, to develop a proof-of-concept technology for drug repurposing targeting rare cancers using a large-scale, high-quality biomedical knowledge graph. The original contract opportunity was a...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
- The National Cancer Institute awarded Nzumbe Inc. a $355,000 firm fixed price definitive contract under the Small Business Innovation Research Concept Award program. This program seeks proposals from small businesses for innovative concepts to advance pediatric and rare cancer therapies, diagnostics, or preventatives. Specifically, Nzumbe will demonstrate technical feasibility and proof-of-concept for a highly innovative pediatric or rare cancer idea through preliminary experiments, while also...
- The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
- This is a $200,000.00 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Nanomaterial Innovation LTD, a woman-owned limited liability company. The contract is for the development of "MULTIFUNCTIONAL SIRNA NANOPARTICLES FOR AML THERAPY", which aligns with NCI's research focus on cancer therapeutics. The contract has a firm fixed price pricing type and was awarded on September 24, 2010 with a...
- <p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase 2 contract worth $299,920.00 to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business in Cambridge, MA. The contract, which is a definitive, firm-fixed-price contract, supports SBIR Topic 314 and has an ultimate completion date of October 21, 2016. The contract is set aside for total small business participation.</p>